E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2258

Related search